% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sachpekidis:141819,
      author       = {C. Sachpekidis$^*$ and L. Larribère$^*$ and A.
                      Kopp-Schneider$^*$ and J. C. Hassel and A.
                      Dimitrakopoulou-Strauss$^*$},
      title        = {{C}an benign lymphoid tissue changes in 18{F}-{FDG}
                      {PET}/{CT} predict response to immunotherapy in metastatic
                      melanoma?315},
      journal      = {Cancer immunology immunotherapy},
      volume       = {68},
      number       = {2},
      issn         = {1432-0851},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2018-02087},
      pages        = {297-303},
      year         = {2019},
      abstract     = {An association between immune-related adverse events
                      (irAEs) caused by immunotherapeutic agents and the clinical
                      benefit of immunotherapy has been suggested. We
                      retrospectively evaluated by means of 18F-FDG PET/CT
                      lymphoid tissue changes in the mediastinal/hilar lymph nodes
                      and the spleen in response to ipilimumab administration in
                      metastatic melanoma.A total of 41 patients with unresectable
                      metastatic melanoma underwent 18F-FDG PET/CT before the
                      start of ipilimumab (baseline PET/CT), after two cycles
                      (interim PET/CT) and at the end of treatment (late PET/CT).
                      Data analysis was focused on the mediastinal/hilar lymph
                      nodes and the spleen. The patients' best clinical response
                      (BCR) was used as reference.According to the BCR reference,
                      31 patients showed disease control (DC) and 10 patients
                      showed progressive disease (PD). Mediastinal/hilar lymph
                      node evaluation revealed that in total 4 patients in the
                      interim or late PET/CT $(10\%)$ demonstrated a 'sarcoid-like
                      lymphadenopathy' as response to treatment (LN-positive). All
                      LN-positive patients responded to ipilimumab with DC. On the
                      other hand, no significant differences between the DC and PD
                      groups regarding both semi-quantitative and quantitative
                      18F-FDG PET spleen-related parameters at baseline and as
                      response to treatment were detected.Based on our findings,
                      $10\%$ patients in the interim or late PET/CT showed
                      'sarcoid-like lymphadenopathy' as response to treatment. All
                      these patients showed disease control, implying a relation
                      between the appearance of sarcoid-like lymphadenopathy and
                      the clinical benefit of anti-CTLA-4 therapy. On the other
                      hand, quantitative 18F-FDG PET analysis of the spleen showed
                      a poor performance in predicting clinical benefit to
                      ipilimumab.},
      cin          = {E060 / A370 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)A370-20160331 /
                      I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30478475},
      doi          = {10.1007/s00262-018-2279-9},
      url          = {https://inrepo02.dkfz.de/record/141819},
}